Member Info for Fruitsnveg

COPD results were good. Scinv's just desperate as always to influence the SP back down to 10p.

-> Interim analysis from the phase 2 trial in COPD patients with confirmed respiratory viral infection found that treatment with SNG001 improved lung antiviral responses compared to placebo. The trial included participants with a range of common respiratory virus infections, including rhinovirus, influenza, adenovirus, respiratory syncytial virus (RSV), human metapneumovirus (HMPV), parainfluenza and coronavirus – although not the specific strain that causes COVID-19. In exacerbating patients who already required treatment with oral corticosteroids and/or antibiotics, treatment with SNG001 also significantly improved lung function compared to those who didn’t receive the drug. Aside from improving outcomes on these measures, SNG001 was also well-tolerated during the treatment period in a high-risk study population, with the mean age of participants being 66 years old. “Overall, SNG001 has now been shown to raise the body’s natural viral defences when challenged by a wide variety of respiratory viruses, indicating that it could be an important treatment in the coming virus season, where there may be coinfection with influenza and other viruses alongside COVID-19,” said Richard Marsden, chief executive officer of Synairgen.

Buys taking over now. GLA.

Thanks for sharing your up-to-date analysis, particularly of the competitor landscape. Hard to get time to pull all of this together as you have done.

Data protection. But don't take my word for it, feel free to contact them just to be sure.

It was a public 'Registered' event. If it's subsequently been made publically available afterwards without registration, taking out Q&A to protect personal data is entirely normal. Legal reasons.
Meelie and Oak are correct.

Correct Richlist. Some 60% Covid-19 have a dry cough, only a third or so have a 'wet', productive cough.

Teamwork, Thanks also for the link. Reassuring headline.

"Synairgen’s inhaled treatment lowers Covid-19 hospitalisation rate."

Soonbetime, IMO, I think the BOD and II's and majority PI's (i.e. those not represented on this BB, we here are but a tiny fraction of overall PI's) would laugh them out of the park at £2. The data and the data alone will determine the price. Going by historical deals in this industry, if the data is good/great/exceptional, Synairgen should expect multiple high ball offers. It all rests on the data. If the data is poor (and there can be no determination of that until data read out despite peoples best efforts to predict), then the future is altogether different. So still lot's to play for IMO. Personally I will holding until at least next data sets are released / or sooner when the FDA move us out of Activ-2 - either upwards into A3, or out of the trials. Interesting weeks ahead.

TLwilliams, I feel you are right - short to mid-term news of Activ-2 or another development (..?..).
I also think Tuesday will see no more than 5-10% drop, then a firm bounce. The market has a short-term memory, especially on a 3 day weekend! In hindsight, the RNS probably came at the best time. We shall see. ATB.

Let's hope so Giovanni.

Still, I'll put my money on them now buying back cheaper. Unless we hear otherwise.

Rewind. Its been a long day, you are right, I am wrong. Thanks for pointing that out :-)

I was aware of that one from 6th, but not the one today. Interesting to see if they buy now back cheaper, a well trodden trading technique...

Thanks Big. Was not aware of that last RNS.

Awaiting evidence to the contrary, if anyone has any?

Feel free to plonk it in a reply to this thread.

Anyone?

Are Polar reducing, or not?

I missed something today as was out a lot - how do we know Polar are reducing. Evidence anyone? The last time someone assured us Polar was buying they actually reduced (marginally). Axe-Capital's call. Well wee, how wrong he was.
So, any evidence for us to know that Polar are reducing, or is it just an opinion?

Thanks

I would also argue that some of those you call "realists" are actual swing traders.
It is in their interest 100% to lower the SP.

"Nobody has a clue about Activ-2’s progression". Don't you think the fact that we are still on Activ-2 , a trial where greater pharmas have fallen and yet we remain, is a clear indication that perhaps, maybe, it's actually progressing fine?

"P3 is palpably and evidentially not going well."

What evidence of there of this may I ask Doc? RM this morning stated "P3 is progressing well". Those are the words of the CEO, not some random opinion spat out here.

From my notes, I can nothing more that he said to indicate that "P3 is palpably and evidentially not going well". Please explain what I have missed ?

I'm not saying you are wrong Wetdream, I agree with you that if there's a better method use it, I'm just stating what RM said about breathlessness in the webinar.